Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Gains from Sales and Divestitures (2012 - 2013)

Gyre Therapeutics (GYRE) reported Gains from Sales and Divestitures of $803484.0 for Q4 2013, down 9.87% year-over-year from $891443.0 in Q4 2012, and down 9.87% on a QoQ basis from $891443.0 in Q4 2012.

Gyre Therapeutics (GYRE) has 2 years of Gains from Sales and Divestitures data on file, last reported at $803484.0 in Q4 2013.

  • Quarterly Gains from Sales and Divestitures fell 9.87% year-over-year to $803484.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $803484.0 (down 9.87% YoY) and the FY2013 annual result came in at $803484.0, down 9.87% from the prior year.
  • Gains from Sales and Divestitures eased to $803484.0 in Q4 2013 per GYRE's latest filing, from $891443.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $891443.0 in Q4 2012 and bottomed at $803484.0 in Q4 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2013 803,484.00
Dec 31, 2013 803,484.00
Dec 31, 2012 891,443.00
Dec 31, 2012 891,443.00